GoodRx Reports Q1 Revenue Decline and 89% Net Income Drop, but Raises Full-Year Guidance

summarizeSummary

GoodRx reported a 4% revenue decrease and an 89.4% net income drop in Q1 2026, driven by declines in prescription transactions, but saw strong growth in Pharma Direct and subscriptions, leading management to raise its full-year 2026 guidance.

check_boxKey Events

• Q1 2026 Financial Performance

  Total revenue decreased 4% year-over-year to $194.0 million, and net income fell 89.4% to $1.2 million, primarily due to a significant downturn in the core prescription transactions business.

• Segment Performance Divergence

  Prescription transactions revenue declined 24% to $113.7 million, while Pharma Direct revenue surged 82% to $52.2 million and subscription revenue increased 16% to $24.4 million.

• Full-Year 2026 Guidance Raised

  Management raised its full-year revenue guidance to $765-$785 million and Adjusted EBITDA expectations to over $235 million, indicating improved outlook despite Q1 results.

• Share Repurchase Activity

  The company repurchased 5.5 million shares of Class A common stock for an aggregate of $12.6 million during the first quarter, with $60.2 million remaining under its authorization.

auto_awesomeAnalysis

GoodRx Holdings reported a challenging first quarter for 2026, with total revenue decreasing 4% year-over-year to $194.0 million and net income plummeting 89.4% to $1.2 million. The core prescription transactions revenue saw a significant 24% decline, attributed to broader changes in the retail pharmacy landscape and lower unit economics. However, the company demonstrated strong growth in its Pharma Direct segment, which surged 82% to $52.2 million, and subscription revenue, which increased 16% to $24.4 million. Despite the Q1 declines, management raised its full-year 2026 revenue guidance to $765-$785 million and Adjusted EBITDA expectations to over $235 million, signaling improved confidence in future performance relative to prior internal forecasts. The company also repurchased 5.5 million shares for $12.6 million during the quarter, reflecting its commitment to capital allocation priorities.